NRXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NRX Pharmaceuticals Inc. is not a good buy for a beginner investor with a long-term perspective at this time. Despite positive analyst ratings and potential FDA catalysts in 2026, the company's current financial struggles, liquidity issues, and lack of immediate positive catalysts make it a risky investment. Additionally, technical indicators and options data do not strongly support a bullish sentiment.
The MACD histogram is positive and expanding, indicating a bullish momentum. However, RSI is in the neutral zone at 76.199, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level (R1: 2.37), which might limit further upside in the short term.
The expanded addressable market and de-risking of the program are also seen as positives.
The company faces severe financial challenges, including a working capital deficit of $19.7 million and limited cash reserves of $7.8 million. Recent earnings reports show no growth in revenue and significant declines in net income and EPS. Investor sentiment is cautious due to these financial struggles.
In Q4 2025, revenue remained stagnant at $983,000 YoY, while net income and EPS dropped by 100%. The company has a gross margin of 54.22%, but liquidity issues and a working capital deficit highlight significant financial risks.
Analysts are optimistic about the company's long-term prospects, with H.C. Wainwright raising the price target to $45 and Ascendiant to $48. Both firms maintain Buy ratings, citing FDA catalysts and expanded market opportunities for NRX-100 and NRX-101 in 2026.
